AMG National Trust Bank Cuts Stake in Pfizer Inc. $PFE

AMG National Trust Bank reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 68,148 shares of the biopharmaceutical company’s stock after selling 1,039 shares during the period. AMG National Trust Bank’s holdings in Pfizer were worth $1,652,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the 1st quarter worth about $27,000. Curio Wealth LLC lifted its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter worth about $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth about $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 1.6%

PFE opened at $24.68 on Friday. The firm has a market capitalization of $140.29 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55. The firm’s 50 day moving average is $24.77 and its 200-day moving average is $24.27. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.64. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

PFE has been the topic of several research reports. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.24.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.